In February 2024, TaurusNXT® Non-glutaraldehyde Crosslinked dry-tissue TAVR system, a thirdgeneration TAVR system internally developed to address the challenges of valve durability, completed all patient enrollment of its pivotal clinical trial. The design of TaurusNXT® is significantly different from TaurusOne® and TaurusElite®. TaurusNXT® uniquely adopts non-glutaraldehyde bio-tissue crosslinking technology for leaflet treatment, which eliminates the root cause of valve calcification, thus solving the problem of prosthetic valve degeneration.